Plasminogen Activation Inhibitor-1 Improves the Predictive Accuracy of Prostate Cancer Nomograms

Shahrokh F. Shariat, Sangtae Park, Quoc Dien Trinh, Claus G. Roehrborn, Kevin M. Slawin, Pierre I. Karakiewicz

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: We tested whether the addition of preoperative circulating plasminogen activator inhibitor type I levels improves the accuracy of standard preoperative and postoperative models for prediction of biochemical recurrence after radical prostatectomy. Materials and Methods: Preoperative plasma levels of plasminogen activator inhibitor type I were measured in 429 consecutive patients treated with radical prostatectomy for clinically localized prostate cancer. The patients were randomly divided into a development (67%, 286) and a split sample validation cohort (33%, 143). Cox regression analysis was used to develop prognostic nomograms for prediction of biochemical recurrence. Results: In standard univariate analyses categorically coded preoperative plasminogen activator inhibitor type I was significantly associated with biochemical recurrence (p <0.001). In standard preoperative and postoperative multivariate analyses preoperative plasminogen activator inhibitor type I was independently associated with biochemical recurrence (p <0.001 and p = 0.002, respectively). In the split sample validation cohort the addition of plasminogen activator inhibitor type I increased the predictive accuracy of the preoperative multivariate model by 1.2%, 7.7%, 10.3%, 6.7% and 5.4% at 1, 2, 3, 4 and 5 years, respectively (p values <0.001). Moreover, the addition of plasminogen activator inhibitor type I increased the predictive accuracy of the postoperative model by 0.5%, 1.1%, 4.0%, 2.4% and 3.6% at 1, 2, 3, 4 and 5 years, respectively (p values <0.001). Conclusions: Preoperative circulating plasminogen activator inhibitor type I is a predictor of biochemical recurrence, and it enhances the accuracy of preoperative and postoperative nomograms. After external validation these nomograms may assist clinical decision making regarding treatment choice and followup as well as identification of patients at high risk for biochemical recurrence who may benefit from neoadjuvant and/or adjuvant treatment.

Original languageEnglish (US)
Pages (from-to)1229-1237
Number of pages9
JournalJournal of Urology
Volume178
Issue number4
DOIs
StatePublished - Oct 2007

Fingerprint

Plasminogen Inactivators
Nomograms
Plasminogen
Prostatic Neoplasms
Recurrence
Prostatectomy
Multivariate Analysis
Regression Analysis
Therapeutics

Keywords

  • nomograms
  • plasminogen inactivators
  • prostatic neoplasms
  • recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Plasminogen Activation Inhibitor-1 Improves the Predictive Accuracy of Prostate Cancer Nomograms. / Shariat, Shahrokh F.; Park, Sangtae; Trinh, Quoc Dien; Roehrborn, Claus G.; Slawin, Kevin M.; Karakiewicz, Pierre I.

In: Journal of Urology, Vol. 178, No. 4, 10.2007, p. 1229-1237.

Research output: Contribution to journalArticle

Shariat, Shahrokh F. ; Park, Sangtae ; Trinh, Quoc Dien ; Roehrborn, Claus G. ; Slawin, Kevin M. ; Karakiewicz, Pierre I. / Plasminogen Activation Inhibitor-1 Improves the Predictive Accuracy of Prostate Cancer Nomograms. In: Journal of Urology. 2007 ; Vol. 178, No. 4. pp. 1229-1237.
@article{0cc5b832a52e4b969665d399300504db,
title = "Plasminogen Activation Inhibitor-1 Improves the Predictive Accuracy of Prostate Cancer Nomograms",
abstract = "Purpose: We tested whether the addition of preoperative circulating plasminogen activator inhibitor type I levels improves the accuracy of standard preoperative and postoperative models for prediction of biochemical recurrence after radical prostatectomy. Materials and Methods: Preoperative plasma levels of plasminogen activator inhibitor type I were measured in 429 consecutive patients treated with radical prostatectomy for clinically localized prostate cancer. The patients were randomly divided into a development (67{\%}, 286) and a split sample validation cohort (33{\%}, 143). Cox regression analysis was used to develop prognostic nomograms for prediction of biochemical recurrence. Results: In standard univariate analyses categorically coded preoperative plasminogen activator inhibitor type I was significantly associated with biochemical recurrence (p <0.001). In standard preoperative and postoperative multivariate analyses preoperative plasminogen activator inhibitor type I was independently associated with biochemical recurrence (p <0.001 and p = 0.002, respectively). In the split sample validation cohort the addition of plasminogen activator inhibitor type I increased the predictive accuracy of the preoperative multivariate model by 1.2{\%}, 7.7{\%}, 10.3{\%}, 6.7{\%} and 5.4{\%} at 1, 2, 3, 4 and 5 years, respectively (p values <0.001). Moreover, the addition of plasminogen activator inhibitor type I increased the predictive accuracy of the postoperative model by 0.5{\%}, 1.1{\%}, 4.0{\%}, 2.4{\%} and 3.6{\%} at 1, 2, 3, 4 and 5 years, respectively (p values <0.001). Conclusions: Preoperative circulating plasminogen activator inhibitor type I is a predictor of biochemical recurrence, and it enhances the accuracy of preoperative and postoperative nomograms. After external validation these nomograms may assist clinical decision making regarding treatment choice and followup as well as identification of patients at high risk for biochemical recurrence who may benefit from neoadjuvant and/or adjuvant treatment.",
keywords = "nomograms, plasminogen inactivators, prostatic neoplasms, recurrence",
author = "Shariat, {Shahrokh F.} and Sangtae Park and Trinh, {Quoc Dien} and Roehrborn, {Claus G.} and Slawin, {Kevin M.} and Karakiewicz, {Pierre I.}",
year = "2007",
month = "10",
doi = "10.1016/j.juro.2007.05.161",
language = "English (US)",
volume = "178",
pages = "1229--1237",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Plasminogen Activation Inhibitor-1 Improves the Predictive Accuracy of Prostate Cancer Nomograms

AU - Shariat, Shahrokh F.

AU - Park, Sangtae

AU - Trinh, Quoc Dien

AU - Roehrborn, Claus G.

AU - Slawin, Kevin M.

AU - Karakiewicz, Pierre I.

PY - 2007/10

Y1 - 2007/10

N2 - Purpose: We tested whether the addition of preoperative circulating plasminogen activator inhibitor type I levels improves the accuracy of standard preoperative and postoperative models for prediction of biochemical recurrence after radical prostatectomy. Materials and Methods: Preoperative plasma levels of plasminogen activator inhibitor type I were measured in 429 consecutive patients treated with radical prostatectomy for clinically localized prostate cancer. The patients were randomly divided into a development (67%, 286) and a split sample validation cohort (33%, 143). Cox regression analysis was used to develop prognostic nomograms for prediction of biochemical recurrence. Results: In standard univariate analyses categorically coded preoperative plasminogen activator inhibitor type I was significantly associated with biochemical recurrence (p <0.001). In standard preoperative and postoperative multivariate analyses preoperative plasminogen activator inhibitor type I was independently associated with biochemical recurrence (p <0.001 and p = 0.002, respectively). In the split sample validation cohort the addition of plasminogen activator inhibitor type I increased the predictive accuracy of the preoperative multivariate model by 1.2%, 7.7%, 10.3%, 6.7% and 5.4% at 1, 2, 3, 4 and 5 years, respectively (p values <0.001). Moreover, the addition of plasminogen activator inhibitor type I increased the predictive accuracy of the postoperative model by 0.5%, 1.1%, 4.0%, 2.4% and 3.6% at 1, 2, 3, 4 and 5 years, respectively (p values <0.001). Conclusions: Preoperative circulating plasminogen activator inhibitor type I is a predictor of biochemical recurrence, and it enhances the accuracy of preoperative and postoperative nomograms. After external validation these nomograms may assist clinical decision making regarding treatment choice and followup as well as identification of patients at high risk for biochemical recurrence who may benefit from neoadjuvant and/or adjuvant treatment.

AB - Purpose: We tested whether the addition of preoperative circulating plasminogen activator inhibitor type I levels improves the accuracy of standard preoperative and postoperative models for prediction of biochemical recurrence after radical prostatectomy. Materials and Methods: Preoperative plasma levels of plasminogen activator inhibitor type I were measured in 429 consecutive patients treated with radical prostatectomy for clinically localized prostate cancer. The patients were randomly divided into a development (67%, 286) and a split sample validation cohort (33%, 143). Cox regression analysis was used to develop prognostic nomograms for prediction of biochemical recurrence. Results: In standard univariate analyses categorically coded preoperative plasminogen activator inhibitor type I was significantly associated with biochemical recurrence (p <0.001). In standard preoperative and postoperative multivariate analyses preoperative plasminogen activator inhibitor type I was independently associated with biochemical recurrence (p <0.001 and p = 0.002, respectively). In the split sample validation cohort the addition of plasminogen activator inhibitor type I increased the predictive accuracy of the preoperative multivariate model by 1.2%, 7.7%, 10.3%, 6.7% and 5.4% at 1, 2, 3, 4 and 5 years, respectively (p values <0.001). Moreover, the addition of plasminogen activator inhibitor type I increased the predictive accuracy of the postoperative model by 0.5%, 1.1%, 4.0%, 2.4% and 3.6% at 1, 2, 3, 4 and 5 years, respectively (p values <0.001). Conclusions: Preoperative circulating plasminogen activator inhibitor type I is a predictor of biochemical recurrence, and it enhances the accuracy of preoperative and postoperative nomograms. After external validation these nomograms may assist clinical decision making regarding treatment choice and followup as well as identification of patients at high risk for biochemical recurrence who may benefit from neoadjuvant and/or adjuvant treatment.

KW - nomograms

KW - plasminogen inactivators

KW - prostatic neoplasms

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=34548452553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548452553&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2007.05.161

DO - 10.1016/j.juro.2007.05.161

M3 - Article

C2 - 17698116

AN - SCOPUS:34548452553

VL - 178

SP - 1229

EP - 1237

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -